CSF1R and neoplasm: Treatments targeting the receptor or its ligand CSF-1R/CSF-1 has been found to improve T-cell responses and combining CSF-1R inhibition with checkpoint blockades or adoptive T-cell transfer therapy resulted in improved anti-tumour T-cell activity and tumour regression [215,218,219].